Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.84 |
| ▸ | PNP | P00491 | 2/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7296117 | 0.98 | MAPT (0.81) | MAPTPNPADORA2BRPS6KA3GDA | |
| SCHEMBL22144 | 0.91 | MAPT (1.00) | MAPTPNPADORA2BRPS6KA3GDA | |
| SCHEMBL5479007 | 0.81 | MAPT (0.62) | MAPTPNPALDH1A1HSD17B10HPGD | |
| Leucopterin SCHEMBL14080077 | 0.80 | MAPT (0.73) | MAPTPNPALDH1A1HSD17B10HPGD | |
| SCHEMBL5479015 | 0.79 | MAPT (0.60) | MAPTPNPADORA2BRPS6KA3ALDH1A1 | |
| SCHEMBL3513712 | 0.78 | MAPT (0.75) | MAPTPNPADORA2BRPS6KA3GDA | |
| SCHEMBL159446 | 0.77 | MAPT (0.68) | MAPTPNPALDH1A1HSD17B10HPGD | |
| Triphosphate SCHEMBL6461190 | 0.75 | MAPT (0.68) | MAPTPNPADORA2BDYRK1AXDH | |
| SCHEMBL1682869 | 0.75 | MAPT (0.68) | MAPTPNPADORA2BRPS6KA3ALDH1A1 | |
| SCHEMBL2206471 | 0.75 | MAPT (0.66) | MAPTPNPALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 615 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119817601-A | Composite microbial agent and application thereof in improving saline-alkali stress resistance of crops | 山东农大肥业科技股份有限公司 | 2025-04-15 | — | — | CN | claimed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | claimed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | claimed |
| EP-3900712-A1 | GPCR HETEROMER INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2021-10-27 | — | — | EP | claimed |
| EP-3727371-A1 | GPCR HETEROMER INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2020-10-28 | — | — | EP | claimed |
| US-20190209594-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2019-07-11 | — | — | US | claimed |
| EP-3452092-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-13 | — | — | EP | claimed |
| WO-2017191300-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-11-09 | — | — | WO | claimed |
| EP-2507241-A1 | METHANOCARBA ADENOSINE DERIVATIVES AND DENDRIMER CONJUGATES THEREOF | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2012-10-10 | — | — | EP | claimed |
| US-20110189255-A1 | DRUG-ELUTING STENTS FOR ADENOSINE RECEPTOR MODULATION | PURDUE RESEARCH FOUNDATION | 2011-08-04 | — | — | US | claimed |
| WO-1994024133-A1 | RING-SUBSTITUTED CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1994-10-27 | — | — | WO | claimed |
| WO-1994022863-A1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1994-10-13 | — | — | WO | claimed |
| WO-1994016704-A1 | OXIME-SUBSTITUTED THERAPEUTIC COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-08-04 | — | — | WO | claimed |
| WO-1994015605-A1 | ACETAL OR KETAL SUBSTITUTED THERAPEUTIC COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-07-21 | — | — | WO | claimed |
| WO-1994011370-A1 | SUBSTITUTED AMINO ALKYL COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-05-26 | — | — | WO | claimed |
| WO-1994011001-A1 | HYDROXYL-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-05-26 | — | — | WO | claimed |
| CN-1047502-A | The preparation method of 8-substituted xanthine | BEECHAM WUELFING GMBH & CO KG (DE) | 1990-12-05 | — | — | CN | claimed |
| EP-0260127-A2 | Xanthine derivatives, their preparation and pharmaceutical compositions containing them | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1988-03-16 | — | — | EP | claimed |
| EP-0107165-B1 | SUBSTITUTED 9H-8-OXO-PYRIMIDO(2,1-F)PURINE-2,4-DIONES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1987-04-15 | — | — | EP | claimed |
| EP-0107165-A1 | Substituted 9H-8-oxo-pyrimido(2,1-f)purine-2,4-diones, process for their production and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1984-05-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | MAPT 3945/4885PNP 2571/4885ADORA2B 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.